Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells

Mechanical Properties of the Cytoskeleton and Cells

(2017) Adrian F. Pegoraro et al.   Cold Spring Harbor Perspectives in Biology

Actin stress fiber organization promotes cell stiffening and proliferation of pre-invasive breast cancer cells

(2017) Sandra Tavares et al.   Nature Communications

Phosphorylation and Activation of RhoA by ERK in Response to Epidermal Growth Factor Stimulation

(2016) Junfeng Tong et al.   PLoS One

PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor

(2016) K Bhattacharya et al.   Oncogenesis

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

(2016) Linda S. Steelman et al.   Aging-US

Stiffness of cancer cells measured with an AFM indentation method

(2015) Kozaburo Hayashi et al.   Journal of the Mechanical Behavior of Biomedical Materials

The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence

(2015) Keyata N. Thompson et al.   Oncotarget

Mechanical phenotype of cancer cells: cell softening and loss of stiffness sensing

(2015) Hsi-Hui Lin et al.   Oncotarget

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

(2015) Nicole M. Davis et al.   Oncotarget

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

(2013) Carolyn D. Britten   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

(2013) Kamal S. Saini et al.   CANCER TREATMENT REVIEWS

The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2

(2013) C Choi et al.   ONCOGENE

Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy

(2013) Cynthia Brito Lins Pereira et al.   PLoS One

A physical sciences network characterization of non-tumorigenic and metastatic cells

(2013)   Scientific Reports

Measuring the Mechanical Properties of Living Cells Using Atomic Force Microscopy

(2013) Gawain Thomas et al.   Jove-Journal of Visualized Experiments

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

(2012) P. J. Roberts et al.   CLINICAL CANCER RESEARCH

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin

(2012) M I Vitolo et al.   ONCOGENE

Cell Stiffness Is a Biomarker of the Metastatic Potential of Ovarian Cancer Cells

(2012) Wenwei Xu et al.   PLoS One

The effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-β

(2011) Jennifer S. Park et al.   BIOMATERIALS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

(2010) Alfonso Sánchez-Muñoz et al.   BMC CANCER

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Deletion of PTEN Promotes Tumorigenic Signaling, Resistance to Anoikis, and Altered Response to Chemotherapeutic Agents in Human Mammary Epithelial Cells

(2009) M. I. Vitolo et al.   CANCER RESEARCH

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

(2009) O. K. Mirzoeva et al.   CANCER RESEARCH

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

(2009) Elena López-Knowles et al.   INTERNATIONAL JOURNAL OF CANCER

AFM indentation study of breast cancer cells

(2008) Q.S. Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Deformability study of breast cancer cells using microfluidics

(2008) H. W. Hou et al.   BIOMEDICAL MICRODEVICES

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

(2008) N. T. Ihle et al.   CANCER RESEARCH

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

(2008) Carolyn Waugh Kinkade et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting RAS and PI3K in lung cancer

(2008) Julian Downward   NATURE MEDICINE